They found that elevated high sensitivity cardiac troponin T (hs-cTnT) levels were common after anthracycline therapy and their elevation at the completion of therapy, in contrast with serial measurement during chemotherapy, may be predictive of cancer therapy-related cardiac dysfunction (CTRCD). Here, TNNT2 is linked to cancer.